[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-tachycardia-vt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-tachycardia-vt":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,41,75,97,138,171,198,217,241,265,286,308,337,362,384,407,435],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100652747","severe-complications-during-ventricular-tachycardia-or-premature-ventricular-complex-ablation-100652747",false,"NCT07777744","Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation","Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation - an International Multicenter Collaborative Study Group","Inclusion Criteria:\n\n* Centers : Centers participating in the present collaborative study group. Invitation to participate will be based either upon personal referral of one of the investigator, previous collaboration or based on a meta-analytic review of the literature published on the subject within the past 20 years.\n* Patients: Females and males of \\>18 years undergoing any type of VT\u002FPVC ablation. While we will accept redo-procedure we will ask for a unique patient-identifier to link procedures belonging to the same patients together.\n* Interventions: VT\u002FPVC ablation (first intervention or re-do) as routinely performed by the participating centers\n* Outcomes: Severe complications, defined as hemodynamic instability requiring mechanical intensive-care management, tamponade, stroke, cardiac arrest, myocardial infarction, phrenic nerve palsies, major bleeding requiring transfusion, vascular or cardiac complication requiring surgery, procedure-related death.\n* Setting: Observational cohort studies, registries, retrospective cohort studies. Data stemming from RCTs (Randomized controlled trials) will not be collected as they likely do not represent a \"real-life\" setting.\n* Length of follow-up: Peri-procedural complications\n* Years considered: Not limited to a specific time-frame, but to reflect common ablation practices, we will focus on data from the 20 past years.\n* Number of patients provided : No lower limit of patients provided per dataset or ablation volume per year to include high- as well as low-volume centers\n\nExclusion Criteria:\n\n* Refusal of the center to participate.\n* Less than 10 procedures available in the dataset (no case reports)\n* Missing essential baseline characteristics, missing collection of sufficient details regarding each complication.","ALL","18 Years",{"count":19,"type":20},15000,"ESTIMATED","OBSERVATIONAL","The investigators aim to characterize patients presenting with a severe ventricular tachycardia (VT) and premature ventricular complex (PVC)-ablation-related complication including patient characteristics, procedural details and subsequent management of the complication by gathering existing patient-level data.",[24,25],"Ventricular Tachycardia (VT)","Premature Ventricular Complexes",[27],"Ablation","RECRUITING","2026-08-17",{"date":31,"type":32},"2026-08-20","ACTUAL",{"date":34,"type":32},"2024-07-01",{"date":36,"type":20},"2028-12-31",{"name":38,"class":39},"University Hospital, Basel, Switzerland","OTHER",25,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100651327","using-non-invasive-mapping-to-eliminate-structural-heart-disease-ventricular-tachycardia-100651327","NCT07759427","Using Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular Tachycardia","Using Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular Tachycardia: a UK Randomised Controlled Trial","UNITE-VT","Inclusion Criteria:\n\n* ≥18 years old\n* Patient with the following:\n\n  * Evidence of post-myocardial infarction\\* structural heart disease.\n  * Cardiac CT and\u002For cardiac MRI scan performed within 6 months.\n  * ICD\u002FCRTD implantation.\n  * Device therapy for VT: at least 1 appropriate ICD shock or 3 ATP episodes within a 6-month period.\n* Suitable candidate for VT ablation as per NHS standard of care.\n* Patient agrees to comply with study procedures and be available for routine follow up visits for at least 6 months after enrolment.\n\nExclusion Criteria:\n\n* Lacks capacity to provide informed consent.\n* Presence of intramural thrombus, tumour or abnormality that precludes vascular access, catheter introduction or manipulations.\n* Coagulopathy, bleeding diathesis or suspected pro-coagulant state.\n* Sepsis, active systemic infection or fever (\\>100.5 F\u002F38 C) within a week prior to the ablation procedure.\n* Renal failure requiring dialysis or renal compromise that in the investigator's judgement would increase risk to the patient or deem the patient inappropriate to participate in the study.\n* Known allergies or intolerance to AADs to be used to treat PVCs.\n* Known allergy for contrast.\n* Female patients who are pregnant or breast feeding.\n* Enrolment in a concurrent interventional clinical study that in the judgement of the investigator would increase risk to the patient or deem them inappropriate to participate in this study.\n* Other conditions that may prevent patients from adhering to the study protocol, in the opinion of the investigator.",{"count":50,"type":20},110,"INTERVENTIONAL",[53],"NA","Ventricular tachycardia (VT) is an abnormal and dangerous heart rhythm affecting the lower chambers of the heart (the ventricles). Patients with structural heart disease caused by previous heart attacks are at an increased risk of developing VT. Current guidelines recommend that patients who develop this abnormal heart rhythm are considered for invasive catheter ablation (ICA). This is an invasive procedure where specialised catheters and a 3D electro anatomical mapping (EAM) system are used to identify the region of the heart responsible for the VT, which is then treated by tissue heating or freezing (ablation). Although significant improvements have been made in both mapping and ablation technologies, these procedures remain technically challenging and time consuming.\n\nView into ventricular onset (VIVO, Catheter Precision) is a non-invasive, mapping system already being used within the NHS. It uses images from previous heart scans, a picture of the patient's chest (taken at the start of the procedure) and a 12-lead electrocardiogram (ECG) tracing, to locate where the VT is coming from. The VIVO map can therefore highlight the likely region of interest for ICA prior to invasive EAM.\n\nThis study will be a prospective, multi-centre, two-arm, non-blinded, randomised controlled trial (RCT). Patients will be evenly randomised (50:50) into a standard VT ablation group and a VIVO guided ablation group. In the VIVO guided ablation group, invasive EAM will be restricted to the region of interest identified using the VIVO map, rather than whole chamber mapping required for standard ablation. The primary objective will be to determine if the VIVO non-invasive mapping system reduces procedure duration and therefore improves workflow efficiency. Secondary objectives will assess the procedural success, safety and patient perceived health benefits of a VIVO guided ablation versus standard ablation.",[24,56],"Catheter Ablation",[58,59,60,61,62,63,64],"Ventricular tachycardia","VT","ablation","non-invasive mapping","procedural VT duration","procedural efficiency","clinical outcomes","2026-08-06",{"date":67,"type":32},"2026-08-12",{"date":69,"type":20},"2026-08-15",{"date":71,"type":20},"2028-02-29",{"name":73,"class":39},"University of Warwick",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":21,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100604452","ventricular-tachycardiaa-registry-study-100604452","NCT07149701","Ventricular Tachycardia：A Registry Study","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention in the investigator's judgment, confirmed by a 12-lead electrocardiogram, ambulatory electrocardiographic monitoring, continuous cardiac monitoring, implantable cardiac device recordings, or electrophysiological study.\n* Structural heart disease diagnosed according to current clinical guidelines.\n* Willing and able to provide written informed consent.\n* Willing to comply with the study follow-up schedule.\n\nExclusion Criteria:\n\n* Ventricular tachycardia secondary to reversible causes (e.g., acute myocardial ischemia or electrolyte disturbances).\n* Idiopathic ventricular tachycardia without evidence of structural heart disease.\n* Cardiac surgery within 60 days before enrollment.\n* Severe infectious diseases (e.g., septic shock or sepsis).\n* Severe coagulation disorders, including platelet count \\\u003C50 × 10⁹\u002FL or disseminated intravascular coagulation.\n* Participation in another interventional clinical study that may interfere with this registry.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation.",{"count":82,"type":20},1000,"1 Year","Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laboratory data, electrophysiological characteristics, treatment strategies, and follow-up outcomes without influencing routine clinical management. The primary effectiveness outcome is a composite of ventricular tachycardia recurrence or appropriate ICD therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death within 12 months. Long-term follow-up will continue to evaluate clinical outcomes, treatment safety, and prognostic factors. The registry is expected to provide high-quality real-world evidence to improve risk stratification, optimize clinical decision-making, and support future clinical research in patients with SHD-VT.",[24,86],"Structural Heart Disease","2026-07-27",{"date":89,"type":32},"2026-07-29",{"date":91,"type":32},"2025-10-14",{"date":93,"type":20},"2029-12-01",{"name":95,"class":39},"Beijing Anzhen Hospital",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":107,"conditions":108,"keywords":116,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100646789","treatment-registry-of-arrhythmias-complications-and-electrocardiograms-in-arrhythmogenic-cardiomyopathies-100646789","NCT07688200","Treatment Registry of Arrhythmias, Complications and Electrocardiograms in Arrhythmogenic CardioMyopathies","Treatment Registry of Arrhythmias, Complications and Electrocardiograms in Arrhythmogenic CardioMyopathies: A Multicenter Retrospective Observational Study","TRACE-ACM","Inclusion Criteria:\n\n* Diagnosis of arrhythmogenic cardiomyopathy, including right-dominant arrhythmogenic right ventricular cardiomyopathy, biventricular arrhythmogenic cardiomyopathy, or left-dominant arrhythmogenic left ventricular cardiomyopathy.\n* ICD implantation.\n* Documented sustained ventricular tachyarrhythmia, including polymorphic ventricular tachycardia, ventricular fibrillation, or monomorphic ventricular tachycardia.\n* Periodic clinical and ICD follow-up.\n* Arrhythmia onset available from ICD electrograms and\u002For ECG recordings.\n* ECG\u002FEGM tracings available for analysis by the steering ECG committee.\n\nExclusion Criteria:\n\n* Incomplete ICD data or incomplete ICD follow-up.\n* Significant coronary artery disease, defined as coronary plaque greater than 50% at coronary angiography or coronary computed tomography angiography.\n* Primary valvular heart disease or congenital heart disease.\n* Infiltrative or inflammatory cardiomyopathies, including sarcoidosis or amyloidosis.\n* Previous exposure to therapies associated with cardiac toxicity, including chemotherapy.",{"count":106,"type":20},300,"TRACE-ACM is a multicenter, retrospective, observational study of patients with arrhythmogenic cardiomyopathy who received an implantable cardioverter-defibrillator (ICD) and had documented ventricular tachyarrhythmias. The study aims to describe the prevalence and type of ICD-related complications, characterize ventricular arrhythmias documented by ICD electrograms and\u002For ECG recordings, and explore associations between clinical, device-related, and treatment-related factors and arrhythmic outcomes.",[109,24,110,111,112,113,114,115],"Arrhythmogenic Cardiomyopathy (AC, ARVD\u002FC)","Ventricular Fibrillation","ICD","ICD Malfunction","ICD SHOCKS","Ventricular Arrhythmias and Cardiac Arrest","Ventricular Arrhythmia",[117,118,119,120,121,122,123,124,125,126,127],"Implantable cardioverter-defibrillator","ICD complications","Arrhythmogenic cardiomyopathy","Monomorphic ventricular tachycardia","Polymorphic ventricular tachycardia","Ventricular fibrillation","ICD electrograms","Arrhythmic storm","Pause-dependent arrhythmia initiation","Catheter ablation","Antiarrhythmic drugs","NOT_YET_RECRUITING","2026-06-30",{"date":131,"type":32},"2026-07-07",{"date":133,"type":20},"2026-07-01",{"date":135,"type":20},"2027-12-31",{"name":137,"class":39},"Policlinico Casilino ASL RMB",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":51,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":170},"100570149","safety-and-performance-assessment-of-the-sphere-9-catheter-and-affera-ablation-system-for-the-treatment-of-ventricular-tachycardia-sphere-9-vt-efs-100570149","NCT06703489","Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)","Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia","Inclusion Criteria:\n\n1. Any of the following:\n\n   1. Ischemic cardiomyopathy (ICM) patients with prior history of myocardial infarction (MI).\n   2. Non-ischemic cardiomyopathy (NICM) patients with documented myocardial scar in a territory without coronary stenosis as evidenced by cardiac imaging.\n2. At least one episode of sustained (continuous for \\>30 seconds or requiring ICD intervention for termination) monomorphic ventricular tachycardia within the 6 months prior to enrollment.\n3. Recurrence of sustained ventricular tachycardia despite class I or III antiarrhythmic drug therapy or ICD intervention.\n4. Implanted with an implantable cardiac defibrillator (ICD) or CRT-D for at least 3 months prior to the ablation procedure.\n5. Age 18 through 85 years old.\n6. Willing and able to provide informed consent.\n7. Willing and able to comply with all pre-, post-, and follow-up testing requirements.\n\nExclusion Criteria:\n\n1. Incessant VT necessitating hemodynamic support prior to the ablation procedure.\n2. Unstable polymorphic VT or ventricular fibrillation (VF).\n3. VTs due to any of the following:\n\n   1. Idiopathic VT\n   2. Automaticity or triggered activity\n   3. Lamin or titin genetic mutation\n   4. Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause (e.g., drug induced arrhythmia).\n4. NICM subjects with active inflammatory processes (e.g., myocarditis) within 120 days prior to the ablation procedure.\n5. VT or VF thought to be from channelopathies.\n6. More than two prior VT ablations at any time, more than one prior VT ablation within 12 months prior to the ablation procedure, or any VT ablation within 4 weeks prior to the ablation procedure.\n7. Sarcoidosis.\n8. Hypertrophic cardiomyopathy, except when due to an apical aneurysm.\n9. Unstable angina.\n10. Active myocardial ischemia.\n11. Type 1 myocardial infarction within 2 months (60 days) prior to the ablation procedure.\n12. Any percutaneous coronary intervention within 2 months (60 days) prior to the ablation procedure.\n13. Any cardiac surgery within 3 months (90 days) prior to the ablation procedure.\n14. Left ventricular ejection fraction (LVEF) \\\u003C15%.\n15. NYHA Class IV heart failure.\n16. Decompensated heart failure.\n17. Currently receiving support, or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO).\n18. Ventricular assist device (VAD) implanted, planned or required for the procedure.\n19. Severe aortic or mitral stenosis, or severe aortic or mitral regurgitation.\n20. Presence of prosthetic valve in the aortic or mitral valve.\n21. Patients with advanced COPD (on home oxygen).\n22. Presence of intracardiac thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation.\n23. Thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the index ablation procedure or with neurologic deficit.\n24. Left atrium (LA) or left ventricle (LV) intracardiac thrombus on imaging.\n25. Severe bleeding, clotting or thrombotic disorder, or thrombocytopenia (defined as platelet count \\\u003C80,000).\n26. Contraindication to anticoagulation.\n27. End-stage renal disease (requiring dialysis).\n28. Acute illness, active infection, or sepsis.\n29. Life expectancy less than 12 months.\n30. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence.\n31. Body mass index \\>45 kg\u002Fm2.\n32. Known ongoing drug or alcohol dependency.\n33. Current or anticipated participation in any other ongoing study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.\n34. Vulnerable subjects (such as a prisoner, handicapped or mentally disabled person, or person under tutelage or guardianship).\n35. Any other condition that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would pose a significant hazard to the subject if an ablation procedure were performed.","85 Years",{"count":147,"type":20},60,[53],"Sphere-9 VT EFS is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, scar-related monomorphic ventricular tachycardia will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.",[24],[152,120,58,153,154,155,156,157,158,159],"Recurrent sustained monomorphic ventricular tachycardia","Arrhythmias, Cardiac","Heart Diseases","Cardiovascular Diseases","Pathologic Processes","Ischemic heart disease","Patient with Implantable Cardioverter Defibrillator (ICD)","Ischemic cardiomyopathy","2026-06-15",{"date":162,"type":32},"2026-06-16",{"date":164,"type":32},"2025-03-18",{"date":166,"type":20},"2027-01",{"name":168,"class":169},"Medtronic Cardiac Ablation Solutions","INDUSTRY",6,{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":181,"studyType":21,"phases":4,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},"100594859","complex-arrhythmia-registry-100594859","NCT07024927","Complex Arrhythmia Registry","Complex Arrhythmia Registry（CAR）： Long-term Outcomes of Catheter Ablation for Atrial Fibrillation or Ventricular Tachycardia： A Multicenter， Prospective Cohort Study","CAR","1. Atrial Fibrillation (AF) Cohort:\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF).\n     3. Scheduled to undergo first-time catheter ablation for AF.\n     4. Procedure to be performed using a 3D mapping system.\n     5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries).\n     2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication).\n     3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment\u002Fprocedure.\n     4. Severe active infection (e.g., septic shock, sepsis).\n     5. Contraindications to anticoagulation therapy.\n     6. Current participation in another interventional clinical trial that may confound the results of this study.\n     7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.\n2. Ventricular Tachycardia (VT) Cohort\n\n   * Inclusion Criteria (Patients must meet ALL of the following criteria):\n\n     1. Age ≥ 18 years.\n     2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including:\n     3. Ischemic heart disease (e.g., prior MI, coronary artery disease).\n     4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)).\n     5. Scheduled to undergo first-time catheter ablation for VT.\n     6. Procedure to be performed using a 3D mapping system.\n     7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments.\n   * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded):\n\n     1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance).\n     2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease).\n     3. Cardiac surgery within 60 days prior to the planned ablation procedure.\n     4. Severe coagulopathy (e.g., platelet count \\\u003C 50 x 10⁹\u002FL, disseminated intravascular coagulation (DIC)).\n     5. Severe heart failure with left ventricular ejection fraction (LVEF) \\\u003C 20%.\n     6. Severe active infection (e.g., septic shock, sepsis).\n     7. Current participation in another interventional clinical trial that may confound the results of this study.\n     8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.",{"count":180,"type":20},4000,"3 Years","This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.",[184,24],"Atrial Fibrillation (AF)",[186,187,60,188],"atrial fibrillation","ventricular tachycardia","registry study","2026-06-02",{"date":191,"type":32},"2026-06-04",{"date":193,"type":32},"2025-10-21",{"date":195,"type":20},"2032-06",{"name":95,"class":39},2,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":197},"100573399","evolution-of-intracardiac-electrograms-recorded-by-left-bundle-branch-pacing-lead-in-patients-with-icd-or-crt-d-100573399","NCT06745778","Evolution of Intracardiac Electrograms Recorded by Left Bundle Branch Pacing Lead in Patients With ICD or CRT-D","Inclusion Criteria:\n\n* Patients aged \\>=18 yrs.\n* Patients indicated for ICD or CRT-D (primary or secondary prevention)\n* Patients who recently (\\\u003C=30 days) received ICD\u002FCRT-D implantation with LBBP\n* Patients' EGM can be digitally recorded\n* Patients are willing to participate in the study and provide signed informed consent\n\nExclusion Criteria:\n\n* Patients received CIED upgrade or replacement with old pacing leads\n* Patients are pregnant\n* Patients participate in another study that will confound this study",{"count":205,"type":20},50,"The goal of this observational study is to investigate the changes of LBB EGM during daily activities and overdrive pacing at the time of peri-implantation and up to 6-month follow-ups of ICD\u002FCRT-D patients. The main question it aims to answer is:\n\n• Does the LBBP lead can provide accurate, stable, and valid EGM for ICD\u002FCRT-D sensing and detection of ventricular tachyarrhythmia events? In each patient intracardiac EGMs of LBBP lead will be collected by ambulatory Holter monitor at the time of peri-implantation and up to 6-month follow-up. EGM collection will be collected at resting and walking conditions and overdrive pacing.",[24,110],"2026-05-06",{"date":210,"type":32},"2026-05-08",{"date":212,"type":32},"2025-02-26",{"date":214,"type":20},"2026-07-31",{"name":216,"class":169},"Medtronic Cardiac Rhythm and Heart Failure",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":145,"enrollmentInfo":224,"targetDuration":4,"studyType":51,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":96},"100637045","dynamic-voltage-mapping-to-personalise-the-ventricular-tachycardia-substrate-100637045","NCT07573579","Dynamic Voltage Mapping to Personalise the Ventricular Tachycardia Substrate","DYNAMITE-VT","Inclusion Criteria:\n\n* Scheduled for clinically indicated VT ablation (due to sustained VT episodes or ICD therapies).\n* Willing and able to give informed consent for participation in the trial\n* Male or female aged between 18-85\n* Ischaemic and non-ischaemic cardiomyopathy\n* ICD insitu\n\nExclusion Criteria:\n\n* Unable or unwilling to consent\n* NYHA Class IV (end stage heart failure)\n* Metastatic cancer\n* End stage renal disease\n* Pregnant or breast feeding\n* Severe frailty",{"count":225,"type":20},40,[53],"Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder and one of the commonest causes of heart-related sudden death. It often affects people who have had a heart attack or other structural heart damage. VT occurs when abnormal electrical circuits develop within and around scar tissue in the heart.\n\nPeople at risk are usually offered an implantable cardiac defibrillator (ICD), a device that can detect VT and deliver a lifesaving shock. While effective, these shocks can be sudden, painful and distressing. Medications such as amiodarone can also help, but they are often unsuitable for long-term use due to their potential side effects on the liver, lungs and thyroid gland.\n\nAn alternative is catheter ablation. Thin tubes (catheters) are threaded from a blood vessel in the groin to the heart, allowing the cardiologist to identify scar tissue and abnormal electrical circuits, which can be destroyed using heat, freezing or electrical energy.\n\nAlthough ablation can help many patients, VT can return in up to one in three people after the procedure. This is because it can be difficult to precisely identify the scar and surrounding tissue that sustain the abnormal circuits, making it challenging to know exactly where to apply ablation treatment.\n\nDynamic Voltage Mapping, is a technique which the investigators believe can more accurately identify scar and the critical bordering tissue during ablation. Initial data collected suggests that the approach accurately predicts the VT circuit and helps guide ablation.\n\nIn this study, the investigators wish to recruit 40 participants undergoing VT ablation to determine how effective Dynamic Voltage Mapping is in real-world procedures.",[24],[56,230,231],"Electroanatomical Mapping","Ventricular Tachycardia","2026-04-30",{"date":234,"type":32},"2026-05-07",{"date":236,"type":20},"2026-08-03",{"date":238,"type":20},"2029-08-01",{"name":240,"class":39},"Liverpool Heart and Chest Hospital NHS Foundation Trust",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":249,"targetDuration":250,"studyType":21,"phases":4,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":96},"100573303","cardiac-radiotherapy-for-ventricular-tachycardia-ii-100573303","NCT06744530","Cardiac RadiothErapy for VEntricular Tachycardia II","Cardiac RadiothErapy for VEntricular Tachycardia II - a Prospective Observational Cohort Study","CREVET II","Inclusion Criteria:\n\n* Eligible for STAR for therapy-refractory VT based on a multidisciplinary discussion\n* Ability to give a written informed consent and willingness to return for follow-up\n\nExclusion Criteria:\n\n* Contra-indications for STAR, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy \\\u003C 6 months in the absence of VT\n* Any condition that is deemed a contraindication in the judgment of the investigators",{"count":205,"type":20},"4 Years","Steoreotactic therapy radioablation has become a standard of care option for patients with therapy-refractory ventricular tachycardia, yet long-term outcome is lacking. The objective of this study is to evaluate the long-term outcomes, both efficacy and safety, after STAR in patients with therapy-refractory ventricular tachycardia.",[24],[187,254,255],"STAR","Stereotactic radiotherapy","2026-04-28",{"date":258,"type":32},"2026-04-29",{"date":260,"type":32},"2025-01-01",{"date":262,"type":20},"2034-12",{"name":264,"class":39},"Universitaire Ziekenhuizen KU Leuven",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":51,"phases":274,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":4},"100631525","sympathetic-ablation-for-ventricular-arrhythmias-100631525","NCT07501819","Sympathetic Ablation for Ventricular Arrhythmias","Early Feasibility Study of Central Sympathetic Nerve Ablation for Treatment of Ventricular Arrhythmias","Inclusion Criteria:\n\n1. Age 18 or older at the time of informed consent\n2. Willing and capable of providing written informed consent\n3. Implanted ICD or CRT-D\n4. Recurrent VT leading to ICD therapy (ATP or shock)\n5. Indicated for catheter ablation of VT per international guidelines\n6. No prior instrumentation or resection of the stellate ganglia, or surgical procedure that may have disturbed the stellate ganglia\n\nExclusion Criteria:\n\n1. Contraindication to percutaneous femoral arterial access\n2. Heparin-induced thrombotic thrombocytopenia\n3. Prior surgical sympathectomy\n4. ECMO therapy in the past 30 days\n5. Contraindicated for advanced heart failure therapies (LVAD or heart transplantation)\n6. A most recently documented LVEF \\\u003C20% in the past 30 days\n7. Receiving inotropic drug therapy\n8. Women of childbearing potential who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test at enrollment\n9. A life expectancy of less than 12 months according to physician judgment\n10. Involvement in any concurrent clinical study with an investigational therapy",{"count":273,"type":20},10,[53],"Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.",[24],"2026-03-24",{"date":279,"type":32},"2026-03-30",{"date":281,"type":20},"2026-04",{"date":283,"type":20},"2027-09",{"name":285,"class":169},"SymKardia",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":51,"phases":295,"briefSummary":296,"conditions":297,"keywords":298,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":96},"100567523","non-invasive-programmed-stimulation-nips-to-guide-the-subsequent-vt-therapeutic-strategies-100567523","NCT06669299","Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies","The Value of Late Non-Invasive Programmed Stimulation (NIPS) in the Setting of Ventricular Tachycardia (VT) Ablation to Guide the Subsequent VT Therapeutic Strategies: a Prospective Randomized Multicenter Study","Inclusion Criteria:\n\n* Patients with an implanted ICD (all brands)\n* Patients who underwent a successful (non-inducibility of any VT) Ventricular Tachycardia Ablation procedure, the \"index procedure\", supported by EnSite Precision or CARTO 3D mapping systems for the following etiologies: previous MI, myocarditis, ARVD, IDCM.\n* Induction of monomorphic VT at NIPS 3-7days after a successful index procedure\n* Age 18 years or more\n* Able to provide an informed consent to participate to the study and available to respect the assessments described in the protocol.\n\nExclusion Criteria:\n\n* Inducible VT after index procedure\n* Contraindication to anticoagulants\n* Presence of thrombi\n* Presence of Mitral and Aortic prosthetic valve\n* Recent (\\\u003C3 months) myocardial infarction or unstable angina or Coronary Artery Bypass\n* Pregnant or nursing\n* Ventricular Tachycardia caused by reversible pathology\n* \\\u003C 1 Year life expectancy according to the investigator",{"count":294,"type":20},51,[53],"The aim of this study is to define the importance of non-invasive programmed stimulation (NIPS) in risk stratification of ventricular tachycardia (VT) recurrence after catheter ablation and to determine the optimal treatment strategy. The primary objective is to establish whether a new VT ablation based on NIPS inducibility will reduce the risk of VT recurrence compared to antiarrhythmic drug therapy.",[24],[299],"Ventricular Tachycardia, VT, Non-Invasive Programmed Stimulation, NIPS, ICD, Implantable Cardioverter Defibrillator",{"date":301,"type":32},"2026-03-27",{"date":303,"type":32},"2025-06-12",{"date":305,"type":20},"2027-12",{"name":307,"class":39},"IRCCS Ospedale San Raffaele",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":4},"100619774","predicting-severe-cardiac-arrhythmias-in-the-perioperative-period-using-ai-ecg-100619774","NCT07348991","Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG","Predicting Atrial Fibrillation and Life-threatening Cardiac Arrhythmias and Conduction Disorders in the Perioperative Period in High Cardiac Risk Surgery Using Artificial Intelligence Elements","Inclusion Criteria:\n\n* Patients over 18 years of age;\n* Scheduled surgery with high cardiac risk\n* Informed consent was given to participate in the study\n\nExclusion Criteria:\n\n* Cancellation of the surgery for any reason;\n* The patient's unwillingness to continue participating in the study;\n* Poor quality of the ECG recording on a single-channel ECG monitor.",{"count":106,"type":20},"During the preoperative examination, in addition to the standard examination recommended before high-risk cardiac surgeries, a digital single-lead ECG is recorded using portable CardioQUARK devices. This ECG is analyzed for time, amplitude, and frequency parameters-more than 200 parameters per cardiac cycle. Additionally, the available parameters of a standard 12-lead ECG recording are determined. All parameters of both single-lead and 12-lead ECGs will be included in a multivariate regression analysis to determine the optimal method for predicting atrial fibrillation, life-threatening cardiac arrhythmias, and conduction abnormalities in the perioperative period after high-risk cardiac procedures.\n\nThe study will include patients undergoing high-risk cardiac surgeries, such as those on the heart, aorta, esophagus, pancreas, liver, and lungs, as well as high-risk oncological surgeries. A partial analysis will also be performed depending on the type of intervention. Rhythm and conduction disturbances will be recorded during surgery, as well as in the postoperative period, using ECG monitors, 24-hour ECG monitoring, and repeated recordings of a standard ECG when complaints or signs of unstable hemodynamics arise",[318,319,320,24,110],"Atrial Fibrillation","Atrioventricular Block, Second and Third Degree","Sinus Node Dysfunction",[322,323,324,325,326,327],"Electrocardiogram","Artificial intelligence","Cardiac arrhythmias","Atrioventricular block","Perioperative","Atrial fibrillation","2026-02-09",{"date":330,"type":32},"2026-02-10",{"date":332,"type":20},"2026-12-31",{"date":334,"type":20},"2028-05-30",{"name":336,"class":39},"I.M. Sechenov First Moscow State Medical University",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":344,"targetDuration":345,"studyType":21,"phases":4,"briefSummary":346,"conditions":347,"keywords":350,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":96},"100608024","electrophysiological-registry-duesseldorf-100608024","NCT07196176","Electrophysiological Registry Duesseldorf","Registry on Electrophysiological Studies (EPS) at University Hospital Düsseldorf","Inclusion Criteria:\n\n* Patients who undergo an electrophysiological study (EPS) or electrical cardioversion at University Hospital Düsseldorf since 2015 (retrospective cohort)\n* Patients scheduled to undergo an EPS or electrical cardioversion at University Hospital Düsseldorf from 2019 onward (prospective cohort) •- Written informed consent for participation in the registry (prospective part only)\n\nExclusion Criteria:\n\n* \\\u003C 18 years\n* Lack of written informed consent\n* Pregnancy",{"count":82,"type":20},"2 Years","This registry at University Hospital Düsseldorf collects retrospective and prospective (from 2019 onward) data on patients undergoing electrophysiological studies (EPS), catheter ablation, and electrical cardioversion. The primary goal is to evaluate safety, efficacy, and clinical outcomes of these standard procedures in routine care. Data will be used for quality assurance and to identify prognostic patient- and procedure-related factors.",[184,348,349,24],"Atrial Flutter","Supraventricular Tachycardias",[186,351,352],"catheter ablation","cardioversion","2025-09-26",{"date":355,"type":32},"2025-09-29",{"date":357,"type":32},"2019-06-01",{"date":359,"type":20},"2031-12-31",{"name":361,"class":39},"Heinrich-Heine University, Duesseldorf",{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":96},"100451457","myocarditis-causing-premature-ventricular-contractionsinsights-from-the-maveric-registry-100451457","NCT05158751","Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry","MAVERIC","Inclusion Criteria:\n\n* Patients \\> 18 years of age with mono-morphic or polymorphic PVC burden of ≥5000 in 24 hours.\n* Non-sustained VT was defined as ≥3 more consecutive beats lasting \\\u003C30 seconds\n\nExclusion Criteria:\n\n* History of myocardial infarction,\n* Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or CT angiography,\n* History of revascularization,\n* Significant symptomatic atrial arrhythmias associated with LV dysfunction,\n* Severe valvular disease,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs,\n* History of cardiac arrest,\n* History of channelopathies or inherited arrhythmias.",{"count":370,"type":20},100,"To assess potential link between unrecognized myocardial inflammation (myocarditis) and premature ventricular contractions (PVCs) associated with and without reduced Left ventricular ejection fraction (LVEF) through comprehensive diagnostic work up.",[373,374,24],"Myocarditis","Premature Ventricular Contractions","2025-08-27",{"date":377,"type":32},"2025-09-04",{"date":379,"type":20},"2026-01",{"date":381,"type":20},"2026-05",{"name":383,"class":39},"Kansas City Heart Rhythm Research Foundation",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":51,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":4},"100599078","clinical-study-on-the-efficiency-of-rapid-arrhythmia-mapping-using-easystars-high-density-mapping-catheter-applications-100599078","NCT07079813","Clinical Study on the Efficiency of Rapid Arrhythmia Mapping Using EasyStars™ High Density Mapping Catheter Applications","Rapid Arrhythm","1. Clinical diagnosis: Ventricular tachycardia (VT)\n\n   * Inclusion criteria:\n\n     1. Patients aged between 18 and 80 years;\n     2. Confirmed diagnosis of ventricular tachycardia (VT) via electrocardiogram (ECG) or 24-hour Holter monitoring;\n     3. The patient has experienced at least one episode of VT in the past 6 months and exhibits symptoms of sustained or paroxysmal ventricular tachycardia;\n     4. The patient meets the criteria for ablation surgery and has clear indications for ablation;\n     5. The patient is in good general health and able to tolerate surgery (no severe underlying heart disease, such as severe heart failure or severe coronary artery disease);\n     6. Voluntarily participates and signs an informed consent form.\n   * Exclusion criteria:\n\n     1. Uncontrolled heart failure (New York Heart Association functional class III-IV);\n     2. History of acute or progressive myocardial infarction;\n     3. Severe pulmonary, hepatic, or renal disease;\n     4. Valvular heart disease or congenital heart disease;\n     5. Excessive use of medications or medication intolerance (e.g., beta-blockers, antiarrhythmic drugs);\n2. Clinical diagnosis: Atrial tachycardia (AT)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with atrial tachycardia (AT) by electrocardiogram (ECG) or Holter monitoring;\n     3. Patients presenting with clinical symptoms such as palpitations, chest tightness, or fatigue;\n     4. Patients diagnosed with persistent or paroxysmal atrial tachycardia and meeting the criteria for ablation therapy;\n     5. Patients who voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease or congenital heart disease;\n     2. Patients with severe left ventricular or right ventricular heart failure;\n     3. Patients with severe systemic diseases, such as liver failure, kidney failure, or tumours;\n     4. Patients with cardiomyopathy or aortic dissection;\n3. Clinical diagnosis: atypical atrial flutter (AFL)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Patients diagnosed with atypical atrial flutter (AFL) via electrocardiogram (ECG) or Holter monitoring;\n     3. Patients with clinical symptoms (e.g., palpitations, chest tightness, fatigue, etc.) that significantly impair their quality of life;\n     4. Patients who meet the criteria for atrial tachycardia ablation and have no other severe comorbidities;\n     5. Voluntarily participate and sign an informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe heart disease, such as cardiomyopathy or severe valvular disease;\n     2. Patients with severe pulmonary disease, such as pulmonary arterial hypertension;\n     3. Patients with a history of major cardiac surgery (e.g., heart transplantation);\n4. Clinically diagnosed with paroxysmal atrial fibrillation (PAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with paroxysmal atrial fibrillation (PAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Frequent episodes of paroxysmal atrial fibrillation with symptoms such as palpitations, fatigue, and dyspnoea, and meeting the criteria for ablation;\n     4. No other severe cardiac or systemic diseases, and meeting the criteria for ablation;\n     5. Voluntarily participating and signing the informed consent form.\n   * Exclusion criteria:\n\n     1. Patients with severe valvular heart disease, aortic dissection, or cardiomyopathy;\n     2. High-risk patients with a history of anticoagulant therapy or currently receiving anticoagulant therapy (e.g., history of thrombosis or stroke);\n     3. Patients with severe underlying conditions such as cancer or severe diabetes;\n5. Clinical diagnosis: Persistent atrial fibrillation (PsAF)\n\n   * Inclusion criteria:\n\n     1. Patients aged 18 to 80 years;\n     2. Diagnosed with persistent atrial fibrillation (PsAF) via electrocardiogram (ECG) or Holter monitoring;\n     3. Atrial fibrillation persisting for more than 7 days and symptoms affecting the patient's quality of life;\n     4. Clear indications for ablation and no other severe comorbidities;\n     5. Voluntarily participating and signing an informed consent form.\n\nExclusion criteria:\n\n1. Presence of severe valvular heart disease or cardiomyopathy;\n2. History of stroke or clinical evidence of thrombus formation;\n3. Severe heart failure (NYHA III-IV class);\n4. High-risk cardiac conditions (e.g., acute myocardial infarction, coronary artery disease); In the above different types of rapid arrhythmias, the inclusion criteria primarily focus on the diagnosis and control of clinical symptoms for different types of arrhythmias, while the exclusion criteria focus on avoiding patients with severe comorbidities or those unable to tolerate surgery. Through this patient screening method, the safety of the study and the accuracy of the data are ensured, thereby enabling a better assessment of the clinical efficacy of the new EasyStars catheter.","80 Years",{"count":106,"type":20},[53],"The primary objective of this study was to evaluate the clinical feasibility, safety, and surgical characteristics of the EasyStars™ High Density Mapping Catheterin in patients with complex arrhythmias.",[24,396,397,398],"Atrial Tachycardia","Typical Atrial Flutter","Paroxysmal Atrial Fibrillation (PAF)","2025-07-28",{"date":401,"type":32},"2025-07-31",{"date":403,"type":20},"2025-08-30",{"date":135,"type":20},{"name":406,"class":169},"Shanghai MicroPort EP MedTech Co., Ltd.",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":51,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":433,"locationsCount":96},"100594995","transcutaneous-vagus-nerve-stimulation-for-ventricular-arrhythmias-100594995","NCT07026695","Transcutaneous Vagus Nerve Stimulation for Ventricular Arrhythmias","Transcutaneous Electrical Vagus Nerve Stimulation for Suppression of Ventricular Arrhythmias","TREAT-VT","PVC Cohort\n\nInclusion Criteria:\n\n* Age \\> 18 years old.\n* Participants must understand and be willing to sign a written informed consent document.\n* PVC burden of \\>10% in a 24-hour period on Holter monitoring.\n\nExclusion Criteria:\n\n* Coronary artery disease\n* Known cardiac disease (heart failure or cardiomyopathy) in the documented absence of PVCs. Individuals with suspected PVC-induced cardiomyopathy heart failure, defined as cardiomyopathy or heart failure only diagnosed in the setting of a \\>10% PVC burden, will be allowed to participate.\n* A known diagnosis of Epilepsy.\n* Ongoing pregnancy or intention to become pregnant in the forthcoming 12 months.\n* Participants using a TENS device for any indication\n\nVT cohort\n\nInclusion Criteria:\n\n* Participants with structural heart disease and a transvenous implantable cardioverter defibrillator (ICD) in situ\n* At least three clinically significant VT events (VT events defined as either \\>30 seconds of sustained VT, appropriate ICD ATP therapies or appropriate ICD shocks) in the six months before enrolment\n\nExclusion Criteria:\n\n* Heart failure syndrome with inotrope dependency or requiring mechanical assistance.\n* Reversible cause of arrhythmia (e.g. culprit electrolyte abnormality or toxin)\n* NYHA (New York Heart Association) stage IV heart failure\n* Myocardial infarction or cardiac surgery in the last six months\n* Life expectancy \\\u003C12 months\n* Ongoing pregnancy or intention to become pregnant in the forthcoming 12 months.\n* Participants using a TENS device for any indication",{"count":416,"type":20},72,[53],"Ventricular arrhythmias are abnormal heart rhythms that arise from the bottom chambers of the heart. They can cause debilitating symptoms when they occur intermittently (these are called premature ventricular ectopics or PVCs) and can be life-threatening when they occur continuously (called ventricular tachycardia or VT). These are the most common causes of sudden cardiac death, especially in patients with pre-existing heart disease.\n\nThey can be a result of overactivation of the sympathetic nervous system, and in extreme circumstances, surgery to cut the nerve may be needed. A novel approach to target this nervous system using a transcutaneous electrical nerve stimulator (TENS) machine has successfully treated arrhythmias that come from the top chambers of the heart (atrial fibrillation). An ear clip is applied for an hour per day connected to a device (smaller than a phone) that can activate the parasympathetic nervous system (that counteracts the sympathetic nervous system). This is called Low-Level Tragus Stimulation (LLTS). Because it has been used for epilepsy for decades, we have evidence of a very high safety profile and tolerability. We plan to enrol 72 patients, 34 with many PVCs and 38 with VT, and randomise them to either first receive LLTS or first receive sham treatment (this will appear the same to the patient and researchers but without any meaningful vibrations being emitted in the sham group). Each patient will then swap over to the other treatment. We will compare whether the LLTS reduces the amount of ventricular arrhythmias during compared to the amount during the sham treatment period. We will use Holter monitors to measure the amount of PVCs after each period in the PVC group. VT patients have an implantable defibrillator that continuously monitors for VT episodes in this group. We will only enrol adults who can give informed consent, and study participation will not interfere with a patient's clinical treatment.",[25,24,420],"Ventricular Arrhythmias",[422,423,424,425,426],"double-blinded","randomized","sham-controlled","crossover","prospective","2025-06-18",{"date":429,"type":32},"2025-06-24",{"date":431,"type":20},"2025-06-15",{"date":135,"type":20},{"name":434,"class":39},"University College, London",{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":51,"phases":444,"briefSummary":445,"conditions":446,"keywords":454,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":96},"100594316","stereotactic-radiosurgery-as-second-line-therapy-for-ventricular-tachycardia-100594316","NCT07017855","Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia","STAR-4VT","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of enrollment.\n2. Presence of structural heart disease (SHD) of either ischemic or non-ischemic etiology.\n3. Implanted ICD or CRT-D device for primary or secondary prevention of sudden cardiac death (SCD).\n4. History of at least one endocardial CA procedure targeting a substrate of monomorphic sVT.\n5. Recurrence of at least one clinically significant and symptomatic episode of monomorphic sVT.\n6. Optimal pharmacological treatment of underlying SHD, including maximally tolerated doses of guideline-recommended heart failure therapies and appropriate antiarrhythmic management.\n7. Provision of written informed consent prior to study participation.\n\nExclusion Criteria:\n\n1. Reversible cause of sVT recurrence, particularly acute coronary syndrome (ACS), acute myocarditis, or lead-related infective endocarditis (LDIE).\n2. Myocardial infarction (MI) or cardiac surgery within the last 40 days.\n3. Idiopathic sVT unrelated to SHD or sVT associated with genetically determined channelopathies.\n4. Ongoing or persistently recurrent hemodynamically unstable sVT until clinical stabilization is achieved.\n5. Acute decompensation of heart failure, classified as New York Heart Association (NYHA) Class IV, until clinical stabilization is achieved.\n6. Worsening angina, classified as Canadian Cardiovascular Society (CCS) Class III or IV until coronary diagnostic evaluation and clinical stabilization are completed.\n7. A mobile thrombus within the left ventricle (LV).\n8. Presence of a left ventricular assist device (LVAD).\n9. Presence of comorbidities or known risk factors for CA complications that, in the judgment of the electrophysiologist, constitute a contraindication to the procedure for safety reasons.\n10. Active, uncontrolled malignancy and\u002For chemotherapy or immunotherapy administered or planned within 1 month of the scheduled ablation procedure.\n11. Features of an active systemic, pulmonary, or pericardial inflammatory process requiring systemic treatment (disease-modifying therapies, corticosteroids, immunosuppressants) within the past 6 months.\n12. Presence of comorbidities or known risk factors for radiotherapy complications that, in the judgment of the radiation oncologist, constitute a contraindication to STAR for safety reasons.\n13. Pregnancy or breastfeeding.\n14. Systemic disease that limits the probability of survival to less than 1 year\n15. Other comorbidities, addictions, or social indications that, in the investigator's opinion, would preclude practical cooperation or otherwise disqualify the patient from participation in the clinical study.\n16. Refusal to participate or lack of written informed consent for study participation.",{"count":443,"type":20},150,[53],"The aim of the study is to compare the efficacy and safety of treating recurrent sustained Ventricular Tachycardia (sVT) after prior Catheter Ablation (CA) in patients with Implanted Cardioverter-Defibrillator (ICD) between re-do of conventional endocardial CA and Stereotactic Arrhythmia Radioablation (STAR).",[447,448,24,449,450,451,452,453],"Ventricular Tachycardia, Monomorphic","Ventricular Tachycardia, Sustained","Ventricular Tachycardia (V-Tach)","Stereotactic Body Radiation Therapy (SBRT)","Stereotactic Techniques","Stereotactic Radiation","Cardioverter-Defibrillators, Implantable",[231,59,455,254,456,111],"Stereotactic Arrhythmia Radioablation","Implanted Cardioverter-Defibrillator","2025-06-04",{"date":303,"type":32},{"date":460,"type":20},"2025-07-01",{"date":462,"type":20},"2028-11-01",{"name":464,"class":39},"Medical University of Silesia"]